Top Page
Fate Therapeutics
(NASDAQ:FATE)
Fate Therapeutics (FATE) vs. SPDR S&P 500 ETF (SPY)
Fate Therapeutics Business Overview & Revenue Model
Fate Therapeutics Earnings Call Summary
Fate Therapeutics Financial Statement Overview
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 8.47M | 13.63M | 63.53M | 96.30M | 55.85M | 31.43M |
| Gross Profit | 5.19M | 13.63M | -93.65M | 82.54M | 50.00M | -94.19M |
| EBITDA | -164.88M | -176.58M | -172.23M | -294.63M | -211.14M | -125.00M |
| Net Income | -171.52M | -186.26M | -160.93M | -281.72M | -212.15M | -173.39M |
Balance Sheet | ||||||
| Total Assets | 371.63M | 440.69M | 506.22M | 705.56M | 921.46M | 622.46M |
| Cash, Cash Equivalents and Short-Term Investments | 222.83M | 279.07M | 315.18M | 436.23M | 615.91M | 482.92M |
| Total Debt | 81.33M | 85.27M | 103.54M | 109.34M | 114.82M | 97.30M |
| Total Liabilities | 110.27M | 121.97M | 137.80M | 221.62M | 242.62M | 238.01M |
| Stockholders Equity | 261.36M | 318.73M | 368.42M | 483.94M | 678.84M | 384.44M |
Cash Flow | ||||||
| Free Cash Flow | -118.77M | -123.60M | -138.42M | -283.77M | -213.57M | -44.16M |
| Operating Cash Flow | -115.61M | -122.87M | -132.26M | -248.21M | -162.87M | -39.23M |
| Investing Cash Flow | 110.54M | 12.22M | 112.67M | 166.75M | -324.02M | -161.08M |
| Financing Cash Flow | 4.46M | 99.89M | 85.00K | 9.21M | 453.13M | 282.84M |
Fate Therapeutics Technical Analysis
Fate Therapeutics Risk Analysis
Fate Therapeutics Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | $154.33M | -7.84 | -35.66% | ― | -48.16% | -97.37% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
| ― | $121.25M | -1.59 | -73.39% | ― | -27.33% | 34.66% | |
| ― | $148.35M | ― | -91.93% | ― | -17.89% | 3.93% | |
| ― | $148.78M | ― | -52.11% | ― | -31.23% | 14.92% | |
| ― | ― | ― | ― | ― | ― | ― | |
| ― | $147.73M | ― | -26.94% | ― | ― | 26.33% |
Fate Therapeutics Corporate Events
Fate Therapeutics Inc. is conducting a Phase 1 clinical study titled ‘A Phase 1, Open-Label Study of FT836, an Off-the-Shelf CAR T-Cell Therapy, With or Without Chemotherapy and/or Monoclonal Antibodies, in Participants With Advanced Solid Tumors.’ The study aims to evaluate the safety and tolerability of FT836, a novel CAR T-cell therapy, in treating various advanced solid tumors, including lung, colorectal, breast, ovarian, endometrial, and head and neck cancers. The primary goal is to establish the recommended phase 2 dose of FT836 in combination with trastuzumab or cetuximab, with or without paclitaxel chemotherapy.
Study Overview: Fate Therapeutics Inc. is conducting a Phase 1 study titled A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease. The study aims to evaluate the safety, pharmacokinetics, and anti-B-cell activity of FT819 in participants with moderate to severe autoimmune conditions such as systemic lupus erythematosus, ANCA-associated vasculitis, idiopathic inflammatory myositis, and systemic sclerosis. This study is significant as it explores a novel treatment approach for these challenging conditions.
Fate Therapeutics Inc. is conducting a Phase 1 study titled A Phase 1 Study of FT825/ONO-8250, an Off-the-Shelf CAR T-Cell Therapy, With or Without Monoclonal Antibodies, in HER2-Positive or Other Advanced Solid Tumors. The study aims to assess the safety, tolerability, and antitumor activity of FT825, a CAR T-cell therapy, with or without monoclonal antibodies in patients with advanced HER2-positive or other solid tumors. This study is significant as it explores innovative treatment options for challenging cancer types.
On October 26, 2025, Fate Therapeutics announced promising results from a Phase 1 clinical trial of its FT819 CAR T-cell therapy for systemic lupus erythematosus (SLE), presented at the ACR Convergence 2025. The trial, involving 10 patients, demonstrated significant reductions in disease activity scores and favorable safety profiles, suggesting potential for outpatient treatment and same-day discharge. The company is also advancing its clinical programs with plans for a pivotal study in 2026, aiming to enhance its market position in autoimmune disease treatment.
The most recent analyst rating on (FATE) stock is a Buy with a $7.00 price target. To see the full list of analyst forecasts on Fate Therapeutics stock, see the FATE Stock Forecast page.
On October 10, 2025, John D. Mendlein and Neelufar Mozaffarian resigned from Fate Therapeutics‘ Board, leading to a reduction in the Board’s size from ten to eight members. Subsequently, on October 13, 2025, Kamal Adawi was appointed as the new Chief Financial Officer, effective October 20, 2025. Adawi, with over 20 years of financial leadership experience in the life sciences industry, is expected to play a crucial role in advancing the company’s financial strategy and supporting its clinical programs, particularly the development of FT819 in systemic lupus erythematosus (SLE).
The most recent analyst rating on (FATE) stock is a Hold with a $1.50 price target. To see the full list of analyst forecasts on Fate Therapeutics stock, see the FATE Stock Forecast page.
Fate Therapeutics Inc. faces a significant risk if its common stock is delisted from the Nasdaq Global Market, as this would negatively impact the liquidity and market price of its shares. The company must adhere to Nasdaq’s minimum requirements, such as maintaining a closing bid price of at least $1.00 per share, to avoid delisting. Failure to meet these criteria could hinder Fate Therapeutics’ ability to raise funds and materially affect the value of investments in the company. This potential delisting poses a substantial threat to the company’s financial stability and investor confidence.
Fate Therapeutics Inc. is a clinical-stage biopharmaceutical company specializing in the development of off-the-shelf, multiplexed-engineered, induced pluripotent stem cell (iPSC)-derived cellular immunotherapies, primarily focusing on innovative treatments in the biotechnology sector.
On August 7, 2025, Fate Therapeutics‘ Board of Directors approved a corporate restructuring to streamline operations, reduce expenses, and extend its cash runway, which includes a 12% reduction in workforce. The restructuring is expected to incur charges of $0.9 million to $1.2 million for severance and related costs in the third quarter of 2025. Additionally, the company reported significant progress in its clinical programs, particularly with its FT819 CAR T-cell product for autoimmune diseases, and plans to expand its trials to include other B cell-mediated autoimmune diseases. Fate Therapeutics is also advancing its pipeline with collaborations and new technologies, aiming to optimize resource allocation and extend its cash runway through the end of 2027.
The most recent analyst rating on (FATE) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Fate Therapeutics stock, see the FATE Stock Forecast page.
Fate Therapeutics Inc. is conducting a Phase 1 study titled A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease. The study aims to evaluate the safety and effectiveness of FT819, a potential treatment for autoimmune diseases such as systemic lupus erythematosus and systemic sclerosis. This study is significant as it explores a novel approach to treating these complex conditions.